Respira Labs’ wearable device listens for lung diseasesUS company Respira Labs has developed a device worn on the chest that uses tiny speakers and microphones Share XRespira Labs’ wearable device listens for lung diseaseshttps://pharmaphorum.com/news/respiras-wearable-device-listens-for-lung-diseases/
NICE changes stance on Sanofi’s Dupixent for severe asthma18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma Share XNICE changes stance on Sanofi’s Dupixent for severe asthmahttps://pharmaphorum.com/news/nice-changes-stance-on-sanofis-dupixent-for-severe-asthma/
ICER says Amgen’s tezepelumab ‘likely to be too expensive’Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it Share XICER says Amgen’s tezepelumab ‘likely to be too expensive’https://pharmaphorum.com/news/icer-says-amgens-tezepelumab-likely-to-be-too-expensive/
Vectura investors ignore critics and back tobacco giant takeoverTobacco giant Philip Morris International (PMI) has won the shareholder vote it needed for its controversial £1.1 billion Share XVectura investors ignore critics and back tobacco giant takeoverhttps://pharmaphorum.com/news/vectura-investors-ignore-critics-and-back-tobacco-giant-takeover/
Amgen builds case for severe asthma drug tezepelumabAmgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in Share XAmgen builds case for severe asthma drug tezepelumabhttps://pharmaphorum.com/news/amgen-builds-case-for-severe-asthma-drug-tezepelumab/
As the smoke clears, Vectura backs tobacco giant PMI’s bidVectura’s board has decided to recommend a takeover bid from tobacco giant Philip Morris International, despite being urged Share XAs the smoke clears, Vectura backs tobacco giant PMI’s bidhttps://pharmaphorum.com/news/as-the-smoke-clears-vectura-backs-tobacco-giant-pmis-bid/
Update: Carlyle baulks at Vectura auction, urges shareholders to back its bidPrivate equity group Carlyle has said it won’t raise its offer for respiratory drug specialist Vectura to match Share XUpdate: Carlyle baulks at Vectura auction, urges shareholders to back its bidhttps://pharmaphorum.com/news/carlyle-baulks-at-vectura-auction-but-urges-shareholders-to-back-its-bid/
Update: Bidding war breaks out for respiratory specialist VecturaA flurry of new offers by Philip Morris International (PMI) and private equity firm Carlyle has hiked the Share XUpdate: Bidding war breaks out for respiratory specialist Vecturahttps://pharmaphorum.com/news/bidding-war-breaks-out-for-respiratory-specialist-vectura/
Big tobacco’s PMI makes another pharma foray with Vectura dealTobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up Share XBig tobacco’s PMI makes another pharma foray with Vectura dealhttps://pharmaphorum.com/news/big-tobaccos-pmi-makes-another-pharma-foray-with-vectura-deal/
